Business Context and Reporting Period
This Form 8-K filing by Processa Pharmaceuticals, Inc. (PCSA) reports on a Special Meeting of Shareholders held on November 14, 2023, in Hanover, Maryland. The filing documents the results of shareholder votes regarding corporate governance and capital structure adjustments.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Shareholder Action
The primary material event reported is the shareholder approval of a proposal to grant the Board of Directors discretionary authority to effect a reverse stock split. Key details include:
- Proposal Approved: Authorization for a reverse stock split of outstanding common stock at a ratio between 1-for-5 and 1-for-30.
- Implementation Timeline: The Board may implement the split on a date no later than March 18, 2024.
- Authorized Shares: The split will occur without a corresponding reduction in the Company's authorized shares.
- Voting Participation: 15,258,183 shares were present, representing approximately 62.0% of outstanding shares as of the September 25, 2023 record date.
Vote Tabulation
| Proposal | For | Against | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Reverse Stock Split | 13,895,377 | 1,341,351 | 21,455 | - |
| Adjournment | 13,814,588 | 1,306,797 | 136,798 | - |
Although the Adjournment Proposal was approved, it was not necessary as the Reverse Stock Split Proposal was successfully passed.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies beyond the procedural details of the shareholder vote. The filing notes that the Company is not an emerging growth company.
Investor Verification Checklist
- Verify the specific reverse stock split ratio selected by the Board of Directors (between 1-for-5 and 1-for-30).
- Confirm the effective date of the reverse stock split, which must be on or before March 18, 2024.
- Monitor subsequent filings for the amended Certificate of Incorporation reflecting the split.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.